QUOTED. 17 February 2020. Ralph Ives.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
“What they’re reducing the tariffs on is not a very large amount of medtech products, as best as we can calculate.” – Ralph Ives, executive VP for global strategy, AdvaMed
Click here for a free trial of Medtech Insight